SCHEMBL1060037

SCHEMBL1060037

CC(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C

nearest known ligand 0.93

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.93
LMNA P02545 1/20 0.93
PGR P06401 1/20 0.93
ALDH1A1 P00352 2/20 0.50
KMT2A Q03164 3/20 0.47
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
MEN1 O00255 2/20 0.44
CYP3A4 P08684 2/20 0.44
ALOX15 P16050 2/20 0.44
POLB P06746 1/20 0.43
MAPT P10636 2/20 0.42
UGT1A1 P22309 1/20 0.42
SQLE Q14534 4/20 0.41
KDM4E B2RXH2 2/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067023 1.00 NR1I2 (0.93) NR1I2LMNAPGRALDH1A1KMT2A
SCHEMBL7106183 1.00 NR1I2 (0.93) NR1I2LMNAPGRALDH1A1KMT2A
SCHEMBL2835876 0.96 NR1I2 (0.86) NR1I2LMNAPGRALDH1A1KMT2A
Lycopene SCHEMBL38650730 0.96 NR1I2 (1.00) NR1I2LMNAPGRALDH1A1KMT2A
Lycopene SCHEMBL29401313 0.96 NR1I2 (1.00) NR1I2LMNAPGRALDH1A1KMT2A
Lycopene SCHEMBL20158 0.96 NR1I2 (1.00) NR1I2LMNAPGRALDH1A1KMT2A
SCHEMBL2833787 0.96 NR1I2 (1.00) NR1I2LMNAPGRALDH1A1KMT2A
Lycopene SCHEMBL21485499 0.96 NR1I2 (1.00) NR1I2LMNAPGRALDH1A1KMT2A
Lycopene SCHEMBL30272252 0.96 NR1I2 (1.00) NR1I2LMNAPGRALDH1A1KMT2A
Lycopene SCHEMBL30471634 0.96 NR1I2 (1.00) NR1I2LMNAPGRALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476546-A2 FUNCTIONALIZATION OF CAROTENOID COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2004-11-17 EP claimed
US-20030182687-A1 Functionalization of carotenoid compounds E.I. DU PONT DE NEMOURS AND COMAPANY 2003-09-25 US claimed
WO-2003068917-A2 FUNCTIONALIZATION OF CAROTENOID COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-08-21 WO claimed
US-11781148-B2 Biological methods for preparing terpenes RADICI CHIMICA S.P.A. (IT) 2023-10-10 US disclosed
US-11332724-B2 Microbial production of terpenoids DSM IP ASSETS B.V. (NL) 2022-05-17 US disclosed
US-20180148697-A1 MICROBIAL PRODUCTION OF TERPENOIDS DSM IP ASSETS B.V. (NL) 2018-05-31 US disclosed
US-9909130-B2 Production of carotenoids in oleaginous yeast and fungi DSM IP ASSETS B.V. (NL) 2018-03-06 US disclosed
EP-3286303-A1 MICROBIAL PRODUCTION OF TERPENOIDS DSM IP Assets B.V. (NL) 2018-02-28 EP disclosed
WO-2016172282-A1 MICROBIAL PRODUCTION OF TERPENOIDS DSM IP ASSETS B.V. (NL) 2016-10-27 WO disclosed
US-9297031-B2 Production of carotenoids in oleaginous yeast and fungi DSM IP ASSETS B.V. (NL) 2016-03-29 US disclosed
EP-2371967-B1 Production of carotenoids in oleaginous yeast and fungi DSM IP ASSETS BV (NL) 2015-06-03 EP disclosed
US-20050221467-A1 Biological production of tetradehydrolycopene E. I. DU PONT DE NEMOURS AND COMPANY 2005-10-06 US disclosed
WO-2005047486-A2 BIOLOGICAL PRODUCTION OF TETRADEHYDROLYCOPENE E.I. DUPONT DE NEMOURS AND COMPANY (US) 2005-05-26 WO disclosed
EP-1476546-A2 FUNCTIONALIZATION OF CAROTENOID COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2004-11-17 EP disclosed
US-20030182687-A1 Functionalization of carotenoid compounds E.I. DU PONT DE NEMOURS AND COMAPANY 2003-09-25 US disclosed
WO-2003068917-A2 FUNCTIONALIZATION OF CAROTENOID COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-08-21 WO disclosed
EP-1238068-A1 DIRECTED EVOLUTION OF BIOSYNTHETIC AND BIODEGRATION PATHWAYS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2002-09-11 EP disclosed
WO-2001042455-A9 DIRECTED EVOLUTION OF BIOSYNTHETIC AND BIODEGRATION PATHWAYS CALIFORNIA INST OF TECHN (US) 2002-05-30 WO disclosed
US-20020051998-A1 Directed evolution of biosynthetic and biodegradation pathways CALIFORNIA INSTITUTE OF TECHNOLOGY 2002-05-02 US disclosed
WO-2001042455-A1 DIRECTED EVOLUTION OF BIOSYNTHETIC AND BIODEGRATION PATHWAYS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2001-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030182687-A1 Functionalization of carotenoid compounds FASN, ALOX12, ADH1A NR1I2 430/4885LMNA 1019/4885PGR 3873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.